Summary

Eligibility
for people ages 18-70 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

This phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Immunotherapy with rituximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.

Official Title

A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

Details

Keywords

Mantle Cell Lymphoma, Lymphoma, Mantle-Cell Lymphoma, Residual Neoplasm, Rituximab, Immunological Antineoplastic Agents, Antibodies, Immunoglobulins, Monoclonal Antibodies, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab and Hyaluronidase Human, auto-HCT, rituximab

Eligibility

Locations

  • UCSF Medical Center-Parnassus
    San Francisco California 94143 United States
  • Contra Costa Regional Medical Center
    Martinez California 94553-3156 United States
  • BASS Medical Group - Lennon
    Walnut Creek California 94598 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
ECOG-ACRIN Cancer Research Group
ID
NCT03267433
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 689 study participants
Last Updated